News Archive
18.June 2008
Algeta begins phase III clinical study of Alpharadin

Oslo, Norway, 18th June 2008 - Algeta ASA, the cancer therapeutics company, has started patient recruitment in a pivotal phase III clinical study of its lead products Alpharadin in men with advanced prostate cancer. Approximately 750 patients are expected to be enrolled at more than 125 medical centers in Europe, Asia, South America and Canada. The primary efficiency endpoint of the trial is overall survival.